<< Back
Dec 14, 2017

Tandem Diabetes Care Announces Issuance of Patent Related to Automated Insulin Delivery Technology

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the issuance of U.S. Patent No. 9,833,177 titled "Insulin Pump Based Expert System." This patent is part of the portfolio of intellectual property acquired by the Company from Smiths Medical ASD, Inc. in 2013. It refers to a pump system that suspends, among other operations, the delivery of insulin if a user's sensor glucose data reaches or falls below an acceptable level, alerts the user and recommends that the user initiate a blood glucose measurement.

"This important patent directly relates to reducing patient risk for hypoglycemia, which is the most valued aspect of automated insulin delivery in our market research," said Kim Blickenstaff, President and Chief Executive Officer of Tandem Diabetes Care. "There is increasing industry focus on automating insulin delivery and the benefits it may provide people with diabetes, and we believe this new patent substantially strengthens Tandem's already robust portfolio of intellectual property in support of these efforts."

U.S. Patent No. 9,833,177 is scheduled to expire in December 2028. The Company has a related U.S. continuation application on file.

Tandem Diabetes Care now has 56 issued U.S. patents and 52 pending U.S. patent applications. In addition, the Company has, and is seeking, patent protection for proprietary technologies in other countries throughout the world.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem manufactures and sells the t:slim X2™ Insulin Pump, the only pump capable of remote feature updates using a personal computer, and the t:flex® Insulin Pump, the first pump designed for people with greater insulin requirements. The t:slim X2 is the only insulin pump available with Dexcom G5® Mobile continuous glucose monitoring (CGM) integration. Tandem is based in San Diego, California.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2, #tflex, #tconnect, and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.

Tandem Diabetes Care and t:flex are registered trademarks, and t:slim X2 is a trademark of Tandem Diabetes Care, Inc. Dexcom and Dexcom G5 are registered trademarks of Dexcom, Inc. All other trademarks are the property of their respective owners.

Forward-Looking Statement

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements relate to, among other things the scope and enforceability of the company's intellectual property, including the expected expiration of the 9,833,177 patent. Many factors could cause the company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including without limitation, those listed under the heading "Risk Factors" in the company's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other documents that Tandem files with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.

Tandem Diabetes Care, Inc.
Media Contact:
Steve Sabicer, 714-907-6264
Investor Contact:
Susan Morrison, 858-366-6900 x7005

Source: Tandem Diabetes Care, Inc.

News Provided by Acquire Media